Abstract
Premature ejaculation (PE) is considered to be the most common sexual problem affecting men, despite the likelihood that it is under-diagnosed. It is a complex condition with many physical and psychological components, making management complicated. It is important to develop treatments for PE as it adversely affects quality of life for individuals and partners.
Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that has been developed principally for the treatment of PE. It is considered more suitable for the treatment of PE than other SSRIs as it can be used as an ‘on demand’ treatment to be taken a few hours before an expected sexual encounter, reducing the possibility of adverse effects.
Dapoxetine may represent a breakthrough in the treatment of PE as it is the first drug to be licensed for this indication. This review attempts to present a balanced benefit-risk assessment of dapoxetine by examining the evidence from phase III clinical trials, focusing on its efficacy in prolonging intravaginal ejaculatory latency time (IELT), patient sexual satisfaction and safety in patients with PE. The benefits and risks of other therapies that are used to treat PE off-licence are also reviewed. There has only been one study to date that directly compares dapoxetine to another therapy, paroxetine, for this indication.
It was found that dapoxetine is most effective at a dose of 60 mg in increasing IELT compared with placebo. All studies have also found that dapoxetine is well tolerated as an ‘on-demand’ therapy and with continual dosing; however, there are little data regarding possible long-term adverse effects. Findings of the dapoxetine development programme demonstrated that dapoxetine is associated with vasovagal-mediated (neurocardiogenic) syncope. No other associated significant cardiovascular adverse events were identified.
Further research is needed to directly compare dapoxetine with other therapies and to investigate the outcomes of dapoxetine used in conjunction with behavioural therapies, and other non-pharmaceutical therapies.
Similar content being viewed by others
References
Linton Wylie Recent advantages in the treatment of premature ejaculation. Drug Des Devel Ther 2010; 4: 1–6
Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomised, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009; 55: 957–68
Kaufman JM, Rosen RC, Mudumbi RV, et al. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2008; 103: 651–8
Althof SE, Abdo CH, Dean J, et al. International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010; 7(9): 2947–69
Ralph D, Wylie K. Ejaculatory disorders and sexual function. BJU Int 2005; 95: 1181–6
Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000
Owen R. Dapoxetine: a novel treatment for premature ejaculation. Drugs Today 2009; 45(9): 669–78
Giuliano F, Clement P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol 2006; 50: 454–66
Shabsigh R, Patrick DL, Rowland DL, et al. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU International 2008; 102: 824–8
Perelman M. A new combunation treatment for premature ejaculation: a sex therapist’s perspective. J Sex Med 2006; 3: 1004–12
Gurkan L, Oommen M, Hellstrom W. Premature ejaculation: current and future treatments. Asian J Androl 2008; 10(1): 102–9
Richardson D, Goldmeier D, Green J, et al. Recommendations for the management of premature ejaculation: BASHH special interest group for sexual dysfunction. Int J STD AIDS 2006; 17: 1–6
Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16(4): 369–81
Kendici M, Salem E, Hellstrom W. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Man 2007; 3: 277–89
Modi NB, Dresser MJ, Simon M, et al. Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006; 46: 301–9
Andersson K, Muhall J, Wyllie M. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel ‘ondemand’ treatment of premature ejaculation. BJU Int 2006; 97: 311–5
McMahon C, Kim SW, Park NC, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010; 7: 256–68
Pryor JL, Althof SE, Steidle C, et al. Efficacy and toler-ability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929–37
Safarinejad M. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. Clin Neuropharmacol 2006; 29: 243–52
Safarinejad M. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. Neuropsycho-pharmacology 2008; 33: 1259–65
Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for as-sessment of erectile dysfunction. Urology 1997; 49(6): 822–30
Modi N. Single and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006; 46: 301–9
Kowey PR, Mudumbi RV, Aquilina JW, et al. Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Drugs R D 2011; 11(1): 1–11
McMahon CG, McMahon CN, Leow LJ, et al. Efficacy of type-5 phosodiesterase inhibitors in the drug treatment of premature ejaculation: a systemic review. BJU Int 2006; 98: 259–72
McMahon C. Dapoxetine for premature ejaculation. Expert Opin Pharmacother 2010; 11: 1741–52
Waldinger M, Zwinderman A, Oliver Antidepressants and ejaculation: a double-blind, randomised, placebo-controlled, fixed-dose study with paroxetine, sertraline and nefazodone. J Clin Psychopharmacol 2001; 21: 293–7
Waldinger M, Zwinderman A, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomised, double-blind, fixed-dose study with stopwatch assessment. Eur Urol 2004; 46: 510–6
Morales A, Barada J, Wyllie M. A review of the current status of topical treatments for premature ejaculation. BJU Int 2007; 100: 493–501
Schapiro B. Premature ejaculation, a review of 1130 cases. J Urol 1943; 50: 374–9
Choi HK, Hung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology 2000; 55: 257–61
Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel, aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2006; 99: 369–75
Kim S, Seo K. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo-controlled study. J Urol 1998; 159:425–7
Wang WF, Wang Y, Minhas S, et al. Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 2007; 14: 331–5
Safarinejad M, Hosseini S. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. J Clin Psychopharmacol 2006; 26(1): 27–31
Salem EA, Wilson SK, Bissada NK, et al. Tramadol HCl has promise in on-demand use to treat premature ejaculation. J Sex Med 2008; 5: 188–93
Joint Formulary Committee. British National Formulary. 60th ed. London: British Medical Association and Royal Pharmaceutical Society, 2010
Mohammed M. Clomipramine as daily dose in the treatment of patients with premature ejaculation: prospective placebo-controlled study. Basrah J Surg 2007; 13: 75–9
Waldinger M. Premature ejaculation: different pathophysiologies and etiologies determine its treatment. J S Marital Ther 2008;34: 1–13
Atan A, Basar MM, Tuncel A, et al. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in the treatment of premature ejaculation. Urology 2006; 67: 388–91
Semans JH. Premature ejaculation: a new approach. South Med J 1956; 49(4): 353–8
Jannini EA, McCabe MP, Salonia A, et al. Organic vs. psychogenic? The Manichean diagnosis in sexual medicine. J Sex Med 2010; 7: 1726–33
Hoy S, Scott L. Dapoxetine in premature ejaculation. Drugs 2010; 1433–43
Murat Basar M, Atan A, Yildiz M, et al. Comparison of sertraline to fluoxetine in regard to their efficacy and side effects in the treatment of premature ejaculation. Arch Esp Urol 1999; 52: 1008–11
Richardson D, Goldmeier D. Pharmacological treatment for premature ejaculation. Int J STD AIDS 2005; 16: 709–11
Acknowledgements
We would like to thank all staff at the Porterbrook Centre, Sheffield, UK, for their generous help and support.
No sources of funding were used to prepare this manuscript. Kevan Wylie was a paid member of the European Advisory Board for Johnson and Johnson. Kate Hutchinson and Kelly Cruickshank have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hutchinson, K., Cruickshank, K. & Wylie, K. A Benefit-Risk Assessment of Dapoxetine in the Treatment of Premature Ejaculation. Drug Saf 35, 359–372 (2012). https://doi.org/10.2165/11598150-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11598150-000000000-00000